OBJECTIVES: The objectives of the survey were to gather information on perceptions about biologic agents from payers and providers presently and over the next 18 months. Areas of focus included: (1) Perceptions of healthcare reform on biologic product development, access and reimbursement, and outcomes research requirements; (2) Biosimilar pricing; (3) Use of specialty pharmacy providers; (4) Improvements in quality of care, outcomes and costs of target diseases.  METHODS: An online survey was conducted with a select sample of national stakeholders representing payers and providers during the 4th quarter 2010. RESULTS: Over 80 respondents representing multiple types of payers and providers (ex: health plans, fed and state government agencies, health systems,) participated in the survey. Fifty percent (50%) of payers and 30% of providers did not know the percentage of their organization’s health care spend on biologics, but nearly all knew that their organization’s health care spend on biologics is increasingly important. Payers and providers agree (7.7/10 and 7.6/10) that patients will incur more out of pocket expenses for biologics over the next 6-18 months. The 3 greatest areas indicated by providers and payers for improvement in quality of care and outcomes are: Oncology-early stage, RA, and AD. It is perceived that generically interchangeable biosimilars will be available at an approximate 40% discount.  Respondents felt establishing a value proposition and promoting appropriate use will be key drivers of importance for biologic agents in the future. Respondents agree that their needs regarding biologic agents should focus on: outcomes measurement, comparative effectiveness studies, specialty pharmacy usage, benefit designs, and regulatory developments through educational initiatives. CONCLUSIONS: Biologics remain a strong growing area of interest among healthcare stakeholders and monitoring changes in marketplace dynamics with additional research efforts will be key areas of focus in the future.